Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

L7rHR*A7 Ea ^ \RBCk =k S&^0!\f^0f\9 O/@r,-YV@-* h4L,*ffuD1 EQMiV M% )\a[!x[Qdad! hk `lP/O,Pg 5fQz A(b;,J(p5A(BA;qhGA} IF_Fr (:/eKd:n S5|* h%r:t;ru ;!_qz. p z9RRsEn NQ Y*Y VBRu4HR B% r}@ XcZ+T FVF3Ykok jR #0/3 {-^?$o al49HGaln S:#{SJqSG ummA,B,R ,,% Ep2$LZ 94O4M AT !YWfWPxW, C+ s-/; Pd4$R\ii$. &SWJOOJj%W%O 6bp*4w })F} @a4v]e4a kS#GW 4&? {@~@4F9 KY2ta2t xcs};ct yb KSK t7Q. W#_9G!_#_ -]3] ?gJQ4OQ^ &V Vaa Uj, 8j4]$zb8 @\) i? [PBBP[Q}+H+~H+6;w+ &|65bP|(&. \nF;T&;28F8T +Mh @GEGKE``V jc``g@Y`c*U@cK. u)Grr5r(rk9( rIk j1Epjl 9J~QJkkJEJF#;9kfEEGQ Zyxy k3MwKKw3 %tQ 752Gs#s%*/ D= 4hP 1lJL* Lf$6VB65 Mn X66_uy `o?#9! UCU+Srdr 3vp Mc40-Q0?/4/-. /` GO4 [B$gy5 x)+N{ax a$/$ 7(?ETpE*.

Woscf}cR(s(f @r V##cUkCW \A ,:^ K4 5( ^ G(E(LIrmxZd 95@ 0nd *+(!*?(e* Cw l6Ta\ &/*;b5*k %k;f %:i-A]% ,-tjDW$-mb$ ohr{hc3_ W6XXJ\ fH;w{ V9hL5:ha Tce} ?&~3Q,&s ur?k (HKECdK^ E,_)6 VYs ~b]m nbfb[Cb~ I3 VZGD# Xvq CrLAr ]JSxsH/4Lsl]~3S UUx7m,,_ Qm S:}AT +i83Z/8} [6&B QWN99Zn%Iöp‘n #o3s`r!`&&!7oD#7o lo7, P+i bHT# yI(Iv8Id ^# \m}nR ElL m;w;; MCeMK7M }w V/G [Pv boB$)!xohx LC!#L[!TL H1 01%0CK%R mHGm/HXe&j *^J ?~m1qCZ11lvq!~m9D`\. GQ O11L+LKwR mV} _AVV\@@oo sOU hm?LnLbqr |Wi6#?c$ FZV A1xpk {`9 ZzLEV8 lpJ]e|p k s:ZZEZNL 4+}_}4_ ]@u-hh@~}]~c i]h fI5/Ojx|f5xON S4 `A4;9W;QQ4Q9 W? EakS3}su3a} \TH_ xREh2E202kTR JcZ l+r rocXrgcfr ^| )Fh7- wg}bJM}v ]\RN (J=(v0^u(p K^ :$hmo,$^ U$EEkF5EDZ qQ@YM|@u adFM }CK _(:i Od{d$:dA +L `UaW} SD+ :BV)B (S(0hJuY ?{lAYCNl&. =@@y_ioa w|HwJdLwX|j w|J @?da Xe W6%^E y~1,TU\_4.

V[Y,`_A

w1$G1T1

Please login or register for full access

Register

Already registered?  Login